Immucell Stock Price, News & Analysis

ImmuCell Corporation (Nasdaq: ICCC) has initiated a CEO succession planning process as current President and CEO Michael F. Brigham announces his intention to retire from full-time work by early 2026. Brigham, who joined ImmuCell in 1989 and has served as CEO since 2000, will turn 65 this fall.

The Board of Directors has already begun the search process, aiming to identify a new leader by year-end 2025. Brigham's financial responsibilities have been transferred to newly hired CFO Timothy C. Fiori. Brigham plans to remain with the company until a successor is found and will continue serving on the Board of Directors through his term ending in June 2026, with potential extended service subject to stockholder approval.

ImmuCell Corporation (ICCC) has announced that its 2025 Annual Meeting of Stockholders will be held virtually on June 12, 2025, at 9:30 AM ET. The meeting will be conducted via telephone conference call and live audio webcast, with stockholders of record as of April 14, 2025, invited to participate. Stockholders can join through a toll-free number or international access line, with Q&A participation limited to telephone participants. The company, which develops products for dairy and beef cattle health, encourages stockholders to vote and submit proxies in advance. A replay will be available for seven days after the meeting. ImmuCell manufactures First Defense® for newborn cattle immunity and is developing Re-Tain® for mastitis treatment.

ImmuCell Corporation (ICCC) reported strong financial results for Q1 2025, with record-breaking performance. Product sales increased 11% to $8.1 million compared to Q1 2024. The company achieved a record quarterly net income of $1.4 million ($0.16 per diluted share), compared to a net loss of ($438,000) in Q1 2024. Gross margin improved to 42% from 32% year-over-year. Cash position strengthened to $4.6 million, up from $3.8 million in December 2024. The company's Adjusted EBITDA reached $2.3 million for the quarter. ImmuCell is working to reduce order backlog and improve margins while advancing its Re-Tain® product through Investigational Product use in the second half of 2025.

ImmuCell Corporation (NASDAQ: ICCC) has announced it will release its unaudited financial results for Q1 2025 after market close on May 14, 2025. The company will host a conference call on May 15, 2025, at 9:00 AM ET to discuss the results. The company maintains its preliminary sales results disclosed on April 8, 2025, with no anticipated changes. The Q1 2025 Form 10-Q filing is expected on May 14, 2025.

ImmuCell, focused on dairy and beef cattle health products, manufactures First Defense® for newborn calf immunity and is developing Re-Tain® for subclinical mastitis treatment in dairy cows. An updated Corporate Presentation will be available on the company's website after market close on May 14.

ImmuCell (ICCC) reported record-breaking preliminary sales results for Q1 2025, achieving $8.1 million in quarterly sales, an 11% increase from Q1 2024. The company's performance showed strong growth with six-month sales reaching $15.8 million (up 28%) and twelve-month sales hitting $27.3 million (up 28%) through March 31, 2025.

The Q1 2025 results exceeded the previous record set in Q4 2024 by 4%, helping reduce the order backlog to $4.0 million from $4.4 million. Production output during Q1 2025 reached approximately 108% of the company's estimated $30 million annual capacity.

Additionally, ImmuCell is initiating Investigational Product use of Re-Tain® through a controlled launch to test market acceptance. The company submitted its Non-Administrative New Animal Drug Application in January 2025, though approval remains pending facility inspections at their contract manufacturer.

ImmuCell (Nasdaq: ICCC) has appointed Timothy C. Fiori as its new Chief Financial Officer. Fiori brings approximately 24 years of finance and commercial operating experience from IDEXX Laboratories in Westbrook, Maine. He holds a B.S. in Finance from the University of Maine (2001).

The company, which develops and manufactures products for dairy and beef cattle health, sees this hire as a strategic move in its growth plan. CEO Michael F. Brigham highlighted that Fiori will help leverage personnel, improve standard costing and financial reporting systems, and enhance business efficiencies.

ImmuCell's key products include First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal restrictions.

ImmuCell (Nasdaq: ICCC) has announced the initiation of Investigational Product use of Re-Tain®, its novel treatment for subclinical mastitis in dairy cows. This controlled launch will help test market acceptance and utilize available inventory before shelf-life expiration, though it's not expected to generate significant revenue or profit.

The company submitted its Non-Administrative New Animal Drug Application (NADA) in early January 2025, including its fourth CMC Technical Section submission along with minor technical sections for All Other Information and Product Labeling. The critical path to NADA approval remains contingent on clearing inspectional observations at the facilities of ImmuCell's contract manufacturer.

This investigational strategy allows ImmuCell to gather product performance data while awaiting full NADA approval. Re-Tain® aims to provide an alternative to traditional antibiotics without FDA-required milk discard or pre-slaughter withdrawal label restrictions.

ImmuCell (ICCC) reported strong financial results for Q4 and full-year 2024, with product sales increasing 52% to $7.8 million in Q4 and $26.5 million for the full year. The company demonstrated significant operational improvements with gross margin expanding to 37% in Q4 2024 from 25% in Q4 2023.

The company achieved positive EBITDA of $1.3 million in Q4 2024, compared to negative ($311,000) in Q4 2023. Net income for Q4 2024 was $515,000 ($0.06 per share), versus a loss of ($1.14 million) in Q4 2023. Cash position strengthened to $3.8 million, up from $979,000 year-over-year.

ImmuCell has operated without contamination issues since April 2024, focusing on improving production yields and gross margins. The company continues to work towards FDA approval for Re-Tain®, with a recent submission of the Non-Administrative NADA in January 2025.

ImmuCell (Nasdaq: ICCC) has announced it will release its unaudited financial results for Q4 and full-year 2024 after market close on February 25, 2025. The company will host a conference call on February 26, 2025, at 9:00 AM ET to discuss these results.

The company confirms there are no changes to the preliminary sales results disclosed on January 9, 2025, and expects to file its Annual Report on Form 10-K by March 31, 2025. An updated Corporate Presentation will be available on the company's website after market close on February 25, 2025.

ImmuCell, which focuses on developing products for dairy and beef cattle health, manufactures First Defense® for newborn calf immunity and is developing Re-Tain® for treating subclinical mastitis in dairy cows without FDA-required milk discard or meat withhold restrictions.